Total Revenue: $121.5 million for Q1 2025, a 62% year-over-year growth. Net Product Sales: $120.4 million for Q1 2025. Royalty Revenue: $1.1 million for Q1 2025. Auvelity Net Product Sales: $96.2 million for Q1 2025, an 80% year-over-year growth. Sunosi Net Product Revenues: $25.2 million for Q1 2025, a 17% year-over-year growth. Cost of Revenue: $9.8 million for Q1 2025. Research and Development Expenses: $44.8 million for Q1 2025. Selling, General and Administrative Expenses: $120.8 million for Q1 2025. Net Loss: $59.4 million or $1.22 per share for Q1 2025. Cash and Cash Equivalents: $300.9 million at the end of Q1 2025. Auvelity Prescriptions: Approximately 167,000 in Q1 2025, a 76% year-over-year growth. Sunosi Prescriptions: Over 46,000 in Q1 2025, a 12% year-over-year growth.

Warning! GuruFocus has detected 2 Warning Sign with AXSM.

Release Date: May 05, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Axsome Therapeutics Inc (NASDAQ:AXSM) reported a 62% year-over-year total revenue growth for the first quarter of 2025, driven by strong demand for Auvelity and Sunosi. The company received FDA approval for Symbravo, its second internally developed product, highlighting its commitment to innovative CNS treatments. Axsome Therapeutics Inc (NASDAQ:AXSM) has a diversified portfolio with multiple late-stage product candidates, including AXS-14, AXS-05, and AXS-12, which are advancing towards regulatory filings. The company announced positive top-line results from several Phase III trials, including solriamfetol in ADHD and Symbravo in migraine patients, reinforcing its robust pipeline. Axsome Therapeutics Inc (NASDAQ:AXSM) maintains a strong cash position with $300.9 million in cash and cash equivalents, sufficient to fund operations into cash flow positivity.

Negative Points

The company reported a net loss of $59.4 million for the first quarter of 2025, although this was an improvement from the previous year's loss. Research and development expenses increased to $44.8 million, driven by multiple Phase III trials and higher personnel costs. Selling, general, and administrative expenses rose to $120.8 million, primarily due to commercialization activities and prelaunch efforts for Symbravo. Despite progress, Axsome Therapeutics Inc (NASDAQ:AXSM) faces challenges in expanding payer coverage for Auvelity, with current coverage at 78% of all lives. The company is closely monitoring potential impacts from trade policy developments, including proposed pharmaceutical tariffs, although it expects any impact to be immaterial.

Story Continues

Q & A Highlights

Q: What has been Axsome's recent interaction with the FDA regarding their developmental agents, particularly AXS-05 for Alzheimer's agitation? A: Mark Jacobson, Chief Operating Officer, stated that the engagement with the FDA remains status quo, with no changes in feedback regarding the planned sNDA submission for AXS-05. The agent has breakthrough therapy designation and is eligible for priority review, which will be determined by the FDA at the time of filing.

Q: When will Axsome initiate DTC advertising for Auvelity, and how do they view the entry of orexins into the narcolepsy market? A: Ari Maizel, Chief Commercial Officer, mentioned that a national DTC campaign for Auvelity is expected to launch later this year. Regarding orexins, Axsome is optimistic about AXS-12, noting its compelling profile and potential market despite the entry of orexins, which still face questions about safety and tolerability.

Q: Can you confirm if the recent settlement with Teva ensures that no generic version of Auvelity can enter the market before 2039? A: Hunter Murdock, General Counsel, confirmed that Teva has 180-day regulatory exclusivity, making it the first generic to launch. Herriot Tabuteau, CEO, added that Axsome plans to pursue additional indications for AXS-05, with Alzheimer's agitation and smoking cessation as the nearest-term opportunities.

Q: How does the sNDA for AXS-05 in Alzheimer's agitation impact its commercial potential and GTN? A: Ari Maizel explained that the sNDA provides clarity for promoting AXS-05 under the Auvelity name. While there are considerations regarding GTN, existing payer contracts and the positive clinical profile are expected to help secure access for the new indication.

Q: What is the expected coverage cadence for Symbravo following its launch, and which additional indications for solriamfetol are most attractive? A: Ari Maizel stated that Axsome is focused on securing access for Symbravo quickly, given its unique clinical profile. Herriot Tabuteau noted that while binge eating disorder is attractive due to limited competition, further results from Phase III trials will determine the most commercially valuable indication.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments